Fatty liver, hepatitis B/C, cirrhosis, gallstones, reflux
A single-arm meta-analysis of diabetic patients with biopsy-proven MASH found SGLT2 inhibitors were associated with improvements in multiple liver, metabolic, and histologic markers versus…
This summary compiles the 2026 joint guidance, describing when to consider resmetirom or semaglutide, how to choose between them, and key monitoring points in non-cirrhotic MASH with…
A systematic review and random-effects meta-analysis showed MASLD and higher liver fibrosis risk are significantly associated with atrial fibrillation (AF) recurrence after catheter…
About 250 million people live with chronic hepatitis B; in Taiwan adult carriage is still 10–13%.
About 1 in 3 adults worldwide has fatty liver; in Taiwan and Japan prevalence is around 30%. Since 2023 it is called MASLD.
Add Beyond CKD to your home screen
Open it like an app, and read articles and tools you have visited even when offline.